Listicle Summary
- 1H Revenue reported at €1.37 billion, slightly below the estimate of €1.38 billion (based on 2 estimates).
- Underlying EBITDA for 1H stands at €387 million.
- Company adjusts its guidance for FY 2024.
- Now expects FY 2024 sales to be at the prior-year level.
- Forecasted FY 2024 underlying EBITDA margin has been reduced to a range of 27%-29% from over 30%.
- Medium-term targets up to 2028 remain unchanged.
- 1H underlying net profit is reported at €165 million.
- Analyst recommendations include 11 buys, 4 holds, and 1 sell.
A look at Sartorius Stedim Biotech Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Smartkarma Smart Scores provide a snapshot of Sartorius Stedim Biotech‘s long-term outlook across key factors. With moderate scores across Value, Dividend, Resilience, and Momentum, the company shows stability and consistency in its performance. Although not the highest, the Growth score of 3 suggests potential for expansion and development in the future. Sartorius Stedim Biotech‘s focus on developing and manufacturing laboratory technologies for various industries positions it as a reliable player in the pharma and food sectors.
Sartorius Stedim Biotech‘s Smart Scores indicate a balanced position in the market, with room for growth and a solid base across key factors. While the company may not lead in any single aspect, its overall outlook appears steady and promising. As a developer and manufacturer of laboratory equipment for a range of sectors, including pharma and food industries, Sartorius Stedim Biotech‘s strategic positioning underscores its importance in supporting research institutes and laboratories.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
